Zevalin Twice in Aggressive Non-Hodgkin Lymphoma
type: MedicalStudy
description: Two Repeated Doses of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) as Salvage Treatment for Patients With Relapsed or Refractory Aggressive B-cell Lymphoma: a Phase II Study.
status: TERMINATED
study design: INTERVENTIONAL
phase: PHASE2
start date: 2008-01
end date: 2011-09
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT00902525
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
study subject: Diffuse Large B-Cell Lymphoma
keywords: PHASE2
keywords: INTERVENTIONAL
keywords: TERMINATED
keywords: Diffuse Large B-Cell Lymphoma

AI Analytics
type: Organization